Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own5.90% Shs Outstand64.74M Perf Week-1.74%
Market Cap8.76B Forward P/E- EPS next Y-1.00 Insider Trans-3.99% Shs Float61.64M Perf Month28.60%
Income-170.10M PEG- EPS next Q-0.77 Inst Own89.10% Short Float15.90% Perf Quarter67.17%
Sales202.80M P/S43.20 EPS this Y84.30% Inst Trans-0.04% Short Ratio5.68 Perf Half Y121.25%
Book/sh12.02 P/B11.26 EPS next Y54.80% ROA-17.60% Target Price190.47 Perf Year299.35%
Cash/sh16.20 P/C8.35 EPS next 5Y-0.20% ROE-25.80% 52W Range32.80 - 176.50 Perf YTD143.24%
Dividend- P/FCF- EPS past 5Y30.00% ROI-14.20% 52W High-23.21% Beta1.42
Dividend %- Quick Ratio12.30 Sales past 5Y32.90% Gross Margin93.70% 52W Low313.20% ATR7.30
Employees255 Current Ratio13.40 Sales Q/Q296.30% Oper. Margin-80.40% RSI (14)60.32 Volatility3.05% 5.93%
OptionableYes Debt/Eq0.55 EPS Q/Q-136.40% Profit Margin-83.90% Rel Volume0.43 Prev Close135.34
ShortableYes LT Debt/Eq0.55 EarningsJul 18 Payout- Avg Volume1.73M Price135.53
Recom1.80 SMA20-1.69% SMA5020.14% SMA20079.68% Volume742,752 Change0.14%
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jan-04-18Initiated Janney Buy $75
Dec-01-17Initiated H.C. Wainwright Buy $75
Oct-06-17Resumed Goldman Buy $71
Oct-02-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Reiterated RBC Capital Mkts Outperform $60 → $64
Apr-28-17Reiterated RBC Capital Mkts Outperform $91 → $60
Apr-05-17Upgrade SunTrust Hold → Buy
Mar-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-02-17Initiated Instinet Buy $84
Mar-01-17Reiterated RBC Capital Mkts Outperform $98 → $91
Jul-16-18 02:53PM  The 5 Best Growth Stocks of 2018 (So Far) Motley Fool
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jul-08-18 08:30PM  [$$] Patients Win With More Access to Treatments The Wall Street Journal
Jul-06-18 11:47AM  Biogen: Let the Situation Cool Off a Bit Before Buying TheStreet.com
Jul-05-18 10:32AM  Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns Zacks
Jul-04-18 08:00PM  [$$] A Risky Drug Approval Lesson The Wall Street Journal
06:00AM  Don't Waste Your Money on Cryptocurrencies, These 3 Stocks Are Better Buys Motley Fool
Jul-03-18 11:05AM  Unexciting Holiday Trading TheStreet.com
09:30AM  3 Best Gene Therapy Stocks of 2018 (So Far) Motley Fool
Jun-29-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:25AM  Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks ACCESSWIRE
Jun-25-18 02:21PM  Sarepta Therapeutics Could Be Onto Something Big Motley Fool
08:53AM  Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress Benzinga
08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-23-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-22-18 09:20AM  Big Biotech Stock Pops and Drops This Week Motley Fool -6.23%
08:41AM  DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus Zacks
Jun-21-18 11:12AM  FAANG Stocks Are Being Nailed TheStreet.com
08:26AM  Is Sarepta Therapeutics Stock Headed to Over $200 a Share? Motley Fool
08:00AM  Trending: Technology Sector Surges to Record Highs Despite Trade Jitters ETF Database
Jun-20-18 03:23PM  Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back TheStreet.com +6.78%
01:47PM  This Biotech Is Cratering On Sarepta's Success But Could Be 'Superior' Investor's Business Daily
10:55AM  Sarepta Pharma Pushes Two Biotech ETFs to New Highs Zacks
10:00AM  Company News For Jun 20, 2018 Zacks
08:48AM  Sarepta shares rocket 40% on promising early results for DMD gene therapy MarketWatch
08:36AM  Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading Benzinga
08:32AM  Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences ACCESSWIRE
07:45AM  Sarepta's Stock Soars on Encouraging Gene Therapy Results Zacks
07:45AM  Recent Analysis Shows First Interstate BancSystem, Spectrum Brands, Sarepta Therapeutics, Capstone Turbine, Main Street Capital, and Insteel Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jun-19-18 11:40PM  [$$] Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatment The Wall Street Journal +36.76%
07:57PM  More tests are needed to develop a gene therapy for a rare genetic disease: Sarepta CEO CNBC
06:10PM  Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday Motley Fool
05:41PM  Why Sarepta Stock Skyrocketed 40% Today Fortune
04:56PM  What Happened in the Stock Market Today Motley Fool
04:54PM  Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend ETF Trends
04:38PM  [$$] Sarepta Shares Up 37% on Gene Therapy Results Barrons.com
04:28PM  Sarepta Gets 'Rousing Applause' And Rockets On Gene Therapy Investor's Business Daily
04:25PM  Why Sarepta Therapeutics Stock Is Blasting Higher Today Motley Fool
04:18PM  Biotech Firm Sarepta Surges 40% on Positive Test Results TheStreet.com
02:18PM  Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations' Benzinga
01:40PM  A Weak Close Is Going to Have a Significant Impact on Sentiment TheStreet.com
01:29PM  Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy TheStreet.com
11:13AM  Cambridge biotech Sarepta tops $9B market cap on gene therapy data American City Business Journals
10:55AM  Sarepta shares rocket 55% on positive early results for DMD gene therapy MarketWatch
10:43AM  Sarepta stock soars as early-stage gene therapy data shows promise Reuters
10:41AM  Sarepta Therapeutics shares soar 50% on positive preliminary results for muscular dystrophy gene therapy CNBC
10:28AM  Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
10:18AM  A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients Forbes
06:18AM  Edited Transcript of SRPT earnings conference call or presentation 19-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
12:10AM  [$$] Sarepta Therapeutics skyrockets on positive study data Financial Times
Jun-17-18 04:16PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-15-18 08:51AM  Options Traders Expect Huge Moves in Sarepta (SRPT) Stock Zacks
Jun-14-18 09:45AM  Sarepta Inks Manufacturing Deal for Gene Therapy Program Zacks
Jun-13-18 08:30AM  Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply GlobeNewswire
Jun-11-18 06:10PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-08-18 08:30AM  Sarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018 GlobeNewswire
Jun-07-18 10:20AM  Biogen's head of late-stage trials leaves for Sarepta American City Business Journals
08:30AM  Sarepta Therapeutics Appoints Gilmore ONeill, M.B., M.M.Sc. as Chief Medical Officer GlobeNewswire
Jun-06-18 08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
Jun-05-18 08:30AM  Sarepta Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
07:25AM  Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy ACCESSWIRE
Jun-04-18 11:31AM  3 Stocks That Tripled in Just 12 Months Motley Fool
08:30AM  Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit GlobeNewswire
Jun-01-18 07:51AM  Sarepta receives negative opinion in Europe for treatment for Duchenne muscular dystrophy MarketWatch
07:00AM  As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe GlobeNewswire
May-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-18 10:09AM  Here's Why Sarepta is Up More Than 60% So Far This Year Zacks
May-16-18 08:19AM  Should Sarepta Therapeutics Incs (NASDAQ:SRPT) Recent Earnings Decline Worry You? Simply Wall St.
May-15-18 06:33AM  These 3 Stocks Have Doubled Investors' Money Motley Fool
May-09-18 03:55AM  Edited Transcript of SRPT earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents +5.62%
May-07-18 08:20AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals ACCESSWIRE
07:30AM  Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy PR Newswire
May-05-18 12:01AM  [$$] Sarepta Raises New Hopes Barrons.com
May-04-18 05:02PM  The Biotech Just Broke Out On Hype Surrounding Its Muscle Disease Drugs Investor's Business Daily +14.81%
04:37PM  Why Sarepta Therapeutics Is Soaring Today Motley Fool
12:34PM  Sarepta Shares Hit 52-Week High on Hopes for New Drugs Barrons.com
11:24AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress Zacks
08:30AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Teva Pharmaceutical Industries ACCESSWIRE
May-03-18 05:38PM  Getting technical: SPY-ville infiltrated by downside Fibonacci and anchored VWAP targets Yahoo Finance Video
05:17PM  Sarepta Therapeutics Plunges As Key Drug Faces Setback In Europe Investor's Business Daily
04:57PM  Sarepta Therapeuticals shares down 5% after company misses Q1 expectations MarketWatch
04:55PM  Sarepta Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies GlobeNewswire
04:01PM  Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
Apr-30-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-27-18 07:35AM  Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem Discovering Underlying Factors of Influence GlobeNewswire
Apr-23-18 08:30AM  Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018 GlobeNewswire
Apr-18-18 02:00PM  Why Big Biotech Stocks May Get An Earnings Boost Investopedia
07:45AM  How BTCY Could Look a Lot Like SRPT in a Year's Time ACCESSWIRE
Apr-12-18 12:10PM  Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid American City Business Journals
Apr-06-18 02:36PM  Sarepta Hit With Call to Drop Duchenne Drug Costs TheStreet.com
Apr-02-18 06:00AM  3 Hot Biotech Stocks Facing Sharp Declines Investopedia
02:43AM  Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report? Zacks
Mar-30-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-18 08:20AM  Todays Research Reports on Trending Tickers: Exelixis and Sarepta Therapeutics ACCESSWIRE
Mar-28-18 04:19PM  Investors sue Solid Biosciences, say they were duped about Duchenne drugs safety American City Business Journals -6.08%
Mar-21-18 11:59AM  Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics Benzinga
05:21AM  Edited Transcript of SRPT earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-20-18 08:30AM  Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program GlobeNewswire
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Howton David TSVP, General CounselJul 16Option Exercise13.8550,000692,69172,719Jul 17 06:01 PM
Howton David TSVP, General CounselJul 16Sale136.4650,0006,823,00034,871Jul 17 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Option Exercise13.7833,782465,41540,690Jul 11 06:05 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Sale137.3233,7824,638,94428,766Jul 11 06:05 PM
Barry RichardDirectorJun 27Sale130.3475,0009,775,5003,170,432Jun 29 06:01 PM
Howton David TSVP, General CounselMar 15Option Exercise22.152,50055,38231,727Mar 16 06:12 PM
Ruff ShamimSVP, Chief Regulatory AffairsMar 15Option Exercise23.932,50059,81329,465Mar 16 06:13 PM
Mahatme SandeshEVP, CFO & CBOMar 15Option Exercise23.852,50059,62543,395Mar 16 06:08 PM
Cumbo AlexanderSVP, Chief Commercial OfficerMar 15Option Exercise20.642,50051,60025,767Mar 16 06:10 PM
Wigzell Hans Lennart RudolfDirectorNov 30Option Exercise7.386,66749,20213,333Dec 04 08:00 PM
Wigzell Hans Lennart RudolfDirectorNov 30Sale55.896,667372,6196,666Dec 04 08:00 PM
INGRAM DOUGLAS SPresident & CEONov 08Buy52.4438,1381,999,957420,196Nov 13 05:00 PM
Ruff ShamimSVP, Regulatory Affairs & QualNov 06Option Exercise14.7610,000147,60037,045Nov 08 08:13 PM
Ruff ShamimSVP, Regulatory Affairs & QualNov 06Sale55.0010,000550,00027,045Nov 08 08:13 PM
Ruff ShamimSVP, Regulatory Affairs & QualOct 03Option Exercise14.7611,500169,74038,545Oct 05 07:24 PM
Ruff ShamimSVP, Regulatory Affairs & QualOct 03Sale50.0011,500575,00027,045Oct 05 07:24 PM
INGRAM DOUGLAS SPresident & CEOJul 27Buy42.5047,0581,999,965382,058Jul 28 08:51 AM
Mahatme SandeshEVP, CFO & CBOJul 21Option Exercise23.851,50035,77533,861Jul 21 09:49 PM
Howton David TSVP, General CounselJul 21Option Exercise20.561,00020,56523,301Jul 21 09:46 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 21Option Exercise14.125,88883,13325,450Jul 21 09:47 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 21Sale44.004,388193,07221,062Jul 21 09:47 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 20Option Exercise13.716,25085,68827,312Jul 21 09:47 PM
Mahatme SandeshEVP, CFO & CBOJul 20Option Exercise15.3850,000769,10765,359Jul 21 09:49 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 20Option Exercise13.712,50034,27522,793Jul 21 09:45 PM
Howton David TSVP, General CounselJul 20Option Exercise13.7125,000342,75041,357Jul 21 09:46 PM
Kaye Edward M. MDDirectorJul 20Sale41.0010,000410,00052,471Jul 21 09:48 PM
Ruff ShamimSVP, Regulatory Affairs & QualJul 20Sale42.006,250262,50021,062Jul 21 09:47 PM
Mahatme SandeshEVP, CFO & CBOJul 20Sale41.0050,0002,050,00032,361Jul 21 09:49 PM
Howton David TSVP, General CounselJul 20Sale41.0025,0001,025,00022,301Jul 21 09:46 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 20Sale41.005,918242,63816,875Jul 21 09:45 PM